PL378120A1 - Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy - Google Patents
Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminyInfo
- Publication number
- PL378120A1 PL378120A1 PL378120A PL37812004A PL378120A1 PL 378120 A1 PL378120 A1 PL 378120A1 PL 378120 A PL378120 A PL 378120A PL 37812004 A PL37812004 A PL 37812004A PL 378120 A1 PL378120 A1 PL 378120A1
- Authority
- PL
- Poland
- Prior art keywords
- sulfonylindazoles
- hydroxytryptamine
- heterocyclyl
- ligands
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44761303P | 2003-02-14 | 2003-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL378120A1 true PL378120A1 (pl) | 2006-03-06 |
Family
ID=32908471
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL378120A PL378120A1 (pl) | 2003-02-14 | 2004-02-10 | Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy |
Country Status (21)
Country | Link |
---|---|
US (3) | US7238696B2 (pl) |
EP (1) | EP1592683A2 (pl) |
JP (1) | JP2006518385A (pl) |
KR (1) | KR20050101551A (pl) |
CN (1) | CN100422171C (pl) |
AR (1) | AR043181A1 (pl) |
AU (1) | AU2004213374A1 (pl) |
BR (1) | BRPI0407253A (pl) |
CA (1) | CA2515570A1 (pl) |
CO (1) | CO5650164A2 (pl) |
CR (1) | CR7930A (pl) |
EC (1) | ECSP055964A (pl) |
MX (1) | MXPA05008438A (pl) |
NO (1) | NO20053792L (pl) |
NZ (1) | NZ541699A (pl) |
PL (1) | PL378120A1 (pl) |
RU (1) | RU2347780C2 (pl) |
TW (1) | TW200505904A (pl) |
UA (1) | UA80184C2 (pl) |
WO (1) | WO2004074243A2 (pl) |
ZA (1) | ZA200506416B (pl) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4323810B2 (ja) * | 2001-04-20 | 2009-09-02 | ワイス | 5−ヒドロキシトリプトアミン−6リガンドとしてのヘテロシクリルオキシ−、−チオキシ−および−アミノベンザゾール誘導体 |
HUP0303801A2 (hu) * | 2001-04-20 | 2004-03-01 | Wyeth | Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
CN1826322B (zh) | 2003-07-22 | 2012-04-18 | 艾尼纳制药公司 | 用于预防和治疗相关病症而作为5-ht2a血清素受体调节剂的二芳基和芳基杂芳基脲衍生物 |
CN101291913A (zh) * | 2005-08-15 | 2008-10-22 | 惠氏公司 | 作为5-羟色胺-6配体的吖嗪基-3-磺酰基吲唑衍生物 |
CN101282938A (zh) | 2005-08-15 | 2008-10-08 | 惠氏公司 | 作为5-羟色胺-6配体的经取代3-磺酰基吲唑衍生物 |
PE20071143A1 (es) * | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
US7645752B2 (en) * | 2006-01-13 | 2010-01-12 | Wyeth Llc | Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors |
EP2001480A4 (en) * | 2006-03-31 | 2011-06-15 | Abbott Lab | Indazole CONNECTIONS |
JP2009532471A (ja) * | 2006-04-05 | 2009-09-10 | ワイス | 5−ヒドロキシトリプタミン−6リガンドとしてのスルホニル−3−ヘテロシクリルインダゾール誘導体 |
WO2007120596A1 (en) * | 2006-04-12 | 2007-10-25 | Wyeth | DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS |
CN101500611A (zh) * | 2006-06-23 | 2009-08-05 | 埃斯蒂维实验室股份有限公司 | 胆碱脂酶抑制剂与具有5-ht6受体亲和力的化合物的组合 |
JP2010527370A (ja) | 2007-05-15 | 2010-08-12 | ワイス・エルエルシー | Cns疾患治療のための5−ヒドロキシトリプタミン−6リガンドとしての5−(アミノアザシクリル)−3−スルホニル−1h−インダゾール |
US20090012308A1 (en) * | 2007-06-13 | 2009-01-08 | Wyeth | Process for the manufacture of benzylsulfonylarenes |
EP2508177A1 (en) | 2007-12-12 | 2012-10-10 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
US20110021538A1 (en) | 2008-04-02 | 2011-01-27 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
WO2009155399A1 (en) * | 2008-06-20 | 2009-12-23 | Wyeth | 1-substituted-3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1h-indazole compounds as 5-hydroxytryptamine-6 ligands |
WO2010062321A1 (en) | 2008-10-28 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto |
JP5696136B2 (ja) * | 2009-04-23 | 2015-04-08 | アッヴィ・インコーポレイテッド | 5−ht受容体調節物質およびその使用方法 |
US8518933B2 (en) * | 2009-04-23 | 2013-08-27 | Abbvie Inc. | Modulators of 5-HT receptors and methods of use thereof |
SG11201610407QA (en) | 2014-07-08 | 2017-01-27 | Sunshine Lake Pharma Co Ltd | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
CA2965741C (en) | 2014-11-03 | 2022-05-17 | Iomet Pharma Ltd | Pharmaceutical compound |
CN104693186B (zh) * | 2014-12-31 | 2017-12-22 | 青岛黄海制药有限责任公司 | 一种吲哚衍生物中c‑f键生成c‑n键合成西泮类药物的方法 |
AU2016276966A1 (en) | 2015-06-12 | 2018-01-18 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder |
TW201720439A (zh) | 2015-07-15 | 2017-06-16 | Axovant Sciences Gmbh | 用於預防及治療與神經退化性疾病相關的幻覺之作為5-ht2a血清素受體的二芳基及芳基雜芳基脲衍生物 |
BR112022026201A2 (pt) | 2020-06-22 | 2023-01-17 | Corcept Therapeutics Inc | Antagonistas do receptor de glicocorticoide de indazol quaternários |
WO2023122600A1 (en) * | 2021-12-21 | 2023-06-29 | Corcept Therapeutics Incorporated | Piperazine indazole glucocorticoid receptor antagonists |
AU2022421212A1 (en) | 2021-12-21 | 2024-07-04 | Corcept Therapeutics Incorporated | Bicyclic indazole glucocorticoid receptor antagonists |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR008245A1 (es) * | 1996-06-21 | 1999-12-29 | Glaxo Group Ltd | Derivados de acido acetico, uso de los mismos en la fabricacion de un agente terapeutico y proceso para preparar dichos derivados |
CA2309150A1 (en) | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Indazole bioisostere replacement of catechol in therapeutically active compounds |
KR100822655B1 (ko) * | 2000-11-02 | 2008-04-17 | 와이어쓰 | 5-하이드록시트립타민-6 리간드로서의 1-아릴설포닐- 또는 1-알킬설포닐-헤테로사이클릴벤즈아졸, 이의 제조방법 및 이를 포함하는 약제학적 조성물 |
BR0116481A (pt) * | 2000-12-22 | 2004-01-06 | Wyeth Corp | Compostos de heterociclilalquilindol ou azaindol como ligandos de 5-hidroxitriptamina-6 |
CA2432654A1 (en) * | 2000-12-22 | 2002-07-04 | Wyeth | Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
TW593278B (en) * | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
JP4323810B2 (ja) * | 2001-04-20 | 2009-09-02 | ワイス | 5−ヒドロキシトリプトアミン−6リガンドとしてのヘテロシクリルオキシ−、−チオキシ−および−アミノベンザゾール誘導体 |
HUP0303801A2 (hu) * | 2001-04-20 | 2004-03-01 | Wyeth | Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
JPWO2002100833A1 (ja) * | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
EP1414442A1 (en) | 2001-08-07 | 2004-05-06 | Smithkline Beecham Plc | 3-arylsulfonyl-7-piperazinyl- indoles, -benzofurans and -benzothiophenes with 5-ht6 receptor affinity for treating cns disorders |
US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
WO2003080608A2 (en) | 2002-03-27 | 2003-10-02 | Glaxo Group Limited | Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
WO2003080580A2 (en) | 2002-03-27 | 2003-10-02 | Glaxo Group Limited | Quinoline derivatives and their use as 5-ht6 ligands |
TW200400177A (en) * | 2002-06-04 | 2004-01-01 | Wyeth Corp | 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands |
JP4754821B2 (ja) * | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
TW200403243A (en) * | 2002-07-18 | 2004-03-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
TW200401641A (en) * | 2002-07-18 | 2004-02-01 | Wyeth Corp | 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands |
WO2004074286A1 (en) * | 2003-02-14 | 2004-09-02 | Wyeth | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands |
DE102004046356A1 (de) * | 2004-09-24 | 2006-03-30 | Clariant Gmbh | Verfahren zur Herstellung von Alk(en)ylphosphorsäureestersalzen |
-
2004
- 2004-02-10 CN CNB2004800094268A patent/CN100422171C/zh not_active Expired - Fee Related
- 2004-02-10 KR KR1020057014910A patent/KR20050101551A/ko not_active Application Discontinuation
- 2004-02-10 EP EP04709911A patent/EP1592683A2/en not_active Withdrawn
- 2004-02-10 AU AU2004213374A patent/AU2004213374A1/en not_active Abandoned
- 2004-02-10 JP JP2006503466A patent/JP2006518385A/ja not_active Ceased
- 2004-02-10 NZ NZ541699A patent/NZ541699A/en unknown
- 2004-02-10 TW TW093103031A patent/TW200505904A/zh unknown
- 2004-02-10 RU RU2005128556/04A patent/RU2347780C2/ru active
- 2004-02-10 MX MXPA05008438A patent/MXPA05008438A/es active IP Right Grant
- 2004-02-10 CA CA002515570A patent/CA2515570A1/en not_active Abandoned
- 2004-02-10 PL PL378120A patent/PL378120A1/pl unknown
- 2004-02-10 BR BR0407253-7A patent/BRPI0407253A/pt not_active IP Right Cessation
- 2004-02-10 WO PCT/US2004/003926 patent/WO2004074243A2/en active Application Filing
- 2004-02-13 US US10/778,427 patent/US7238696B2/en not_active Expired - Fee Related
- 2004-02-13 AR ARP040100459A patent/AR043181A1/es unknown
- 2004-10-02 UA UAA200508735A patent/UA80184C2/uk unknown
-
2005
- 2005-08-03 CR CR7930A patent/CR7930A/es not_active Application Discontinuation
- 2005-08-10 CO CO05079298A patent/CO5650164A2/es not_active Application Discontinuation
- 2005-08-10 NO NO20053792A patent/NO20053792L/no not_active Application Discontinuation
- 2005-08-11 ZA ZA200506416A patent/ZA200506416B/xx unknown
- 2005-08-11 EC EC2005005964A patent/ECSP055964A/es unknown
-
2007
- 2007-05-15 US US11/803,531 patent/US7560470B2/en not_active Expired - Fee Related
-
2009
- 2009-06-12 US US12/483,344 patent/US20090253711A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
RU2347780C2 (ru) | 2009-02-27 |
MXPA05008438A (es) | 2005-10-19 |
AU2004213374A1 (en) | 2004-09-02 |
JP2006518385A (ja) | 2006-08-10 |
EP1592683A2 (en) | 2005-11-09 |
TW200505904A (en) | 2005-02-16 |
CN100422171C (zh) | 2008-10-01 |
CA2515570A1 (en) | 2004-09-02 |
WO2004074243A3 (en) | 2004-12-02 |
AR043181A1 (es) | 2005-07-20 |
BRPI0407253A (pt) | 2006-01-31 |
CO5650164A2 (es) | 2006-06-30 |
US20040167122A1 (en) | 2004-08-26 |
CN1771244A (zh) | 2006-05-10 |
US20090253711A1 (en) | 2009-10-08 |
US7560470B2 (en) | 2009-07-14 |
KR20050101551A (ko) | 2005-10-24 |
ECSP055964A (es) | 2006-01-16 |
UA80184C2 (en) | 2007-08-27 |
US20070232618A1 (en) | 2007-10-04 |
NO20053792L (no) | 2005-08-10 |
CR7930A (es) | 2006-02-07 |
ZA200506416B (en) | 2007-02-28 |
US7238696B2 (en) | 2007-07-03 |
RU2005128556A (ru) | 2006-01-27 |
NZ541699A (en) | 2009-01-31 |
WO2004074243A2 (en) | 2004-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200506416B (en) | Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands | |
ZA200500435B (en) | 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands | |
ZA200500437B (en) | 1-heterocyclyalkyl-3-sulfonazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | |
IL174020A0 (en) | Antigen-scaffold complexes | |
HK1071371A1 (en) | 1-(Aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands | |
SG126757A1 (en) | Organometallic compounds | |
EP1638626A4 (en) | PUMP | |
IL157059A0 (en) | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
IL158445A0 (en) | Heterocyclyloxy-, -thioxy-and-aminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
PL370890A1 (pl) | Pochodne azaindoliloalkiloaminy jako ligandy receptora 5-hydroksytryptaminy-6 | |
IL174305A0 (en) | 5-arylpyrimidines as anticancer agents | |
AU2003272511A8 (en) | Cd44-binding ligands | |
HK1065949A1 (en) | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | |
IL158448A0 (en) | Heterocyclylalkoxy- alkylthio-and-alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands | |
GB0419645D0 (en) | Hinged-vane rotary pump | |
ZA200801524B (en) | Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands | |
IL189476A0 (en) | Substituted - 3 - sulfonylindazole derivatives as 5 - hydroxytryptamine-6 ligands | |
IL176323A0 (en) | Self-remediating filter | |
IL180198A0 (en) | Indolylalkylamine metabolites as 5 - hydroxytryptamine - 6 ligands | |
GB0226374D0 (en) | Ligands | |
IL174218A0 (en) | Ligands | |
EP1671033A4 (en) | PUMP | |
GB0230202D0 (en) | Ligand | |
GB0313709D0 (en) | Ligands | |
GB0302157D0 (en) | Pump |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |